Skip to content
The Future Explorerby Benjamin Talin
The Closing of the Planetary EnvelopeIn the book · Ch. 11Megatrend

AMR & zoonotic risk

Zoonotic and Antimicrobial Resistance Risk

Two hidden health risks growing side by side. 'Antimicrobial resistance' means germs learning to survive the medicines we use against them, helped by heavy antibiotic use on farms. 'Zoonotic' means diseases that jump from animals to people, which happens more as forests are cut and the climate warms. Drug-resistant bacteria already directly kill more than a million people a year, and up to 80% of the antibiotics people and animals take leave the body unchanged.

Resistance rises; spillover risk grows with habitat disruption and warming.

2.5/ 5

Gradient 2.5 / 5 - weighed down most by the weakest enabler.

The average of these enablers is 2.6. The ramp runs at 2.5.

Shared weakest link at 2: Epistemic Trust, Synthetic Biology. The ramp is held back by all of them at once, and deepening one alone lifts it only a little.

6 enablers have to mature together before this ramp steepens.

In the network

Its enablers on the left, least mature first and drawn largest; the megatrends it is coupled with on the right. A thicker line is a heavier weight; the arrow shows which way a coupling pushes.weakest linkamplifies

Also shaped by The Collapse of Shared Reality (1 shared enabler, 1 coupling) · The Inversion of the Population Pyramid (3 shared enablers) · The Optimisation of Everything (1 shared enabler) · The Rebuild of the Physical Base (5 shared enablers, 1 coupling)

Enablers

EnablerFamilyWeightMaturityRole
Epistemic Trusthumanmoderate
2/5
shared weakest link (with 1 other)
Synthetic Biologytechnologicalmoderate
2/5
shared weakest link (with 1 other)
BioTech & Genomicstechnologicalmoderate
3/5
-
Gene Editingtechnologicalmoderate
3/5
-
Vaccine Platforms & Antimicrobialstechnologicallarge
3/5
-

The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull. Everything above 2 is strength this ramp can use only in part until the weakest link moves.

What this pushes on, and what pushes on it

Bound by

Agricultural antibiotic practice and pharma investment

The economics of antibiotic development (low return) and the politics of agricultural reform (high resistance).

Momentum. Biological and compounding. Resistance accumulates as long as antibiotics are used, and use is rising fastest in agriculture.

The four clocks

Four systems absorb this at four speeds. The distance between them is the adaptation gap.

Individuals

months

Fast to demand an antibiotic, and the demand is part of the mechanism.

Companies

years

The pharmaceutical industry has largely exited, rationally, because the best public-health outcome is the worst commercial one.

Governments

decades

Advance purchase commitments and subscription models exist and are far below the scale the curves imply.

The biosphere

not ours to set

Habitat disruption and warming raise spillover risk on their own schedule, independent of any health system.

Impacts by domain

Social & demographic

Antibiotic resistance is already a leading cause of death, not a future threat: drug-resistant bacteria directly caused 1.14 million deaths in 2021 and were associated with 4.71 million in all worldwide (GBD 2021 Antimicrobial Resistance Collaborators, The Lancet, September 2024).

Environmental

Antibiotics do not stay in the body: up to 80% of the antibiotics given to people and animals are excreted unmetabolised in urine and faeces (UN Environment, Frontiers Report 2017, as reported by CIDRAP).

Economic

Resistant infections are an expensive complication hospitals didn't budget for: treating multidrug-resistant infections cost US hospitals $4.6 billion in 2017, with the worst cases running to over $74,000 per patient (Nelson et al., Clinical Infectious Diseases, January 2021).

Geopolitical

Contested: most countries have a plan on paper and no money to run it: 93% of 177 countries surveyed had a national action plan on antimicrobial resistance in 2023, but only 40% had secured funding to actually operate it (Quadripartite TrACSS, May 2024).

What would prove this wrong

Resistance rates falling in a major economy following an agricultural antibiotic restriction, or a novel antibiotic class reaching market under a pull incentive that makes the economics work.

Talin, B. (2026). Zoonotic and Antimicrobial Resistance Risk. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/m/zoonotic-and-antimicrobial-resistance-risk/